Literature DB >> 22571957

Relations between plasma von Willebrand factor or endothelin-1 and restenosis following carotid artery stenting.

Hua Yang1, Jian-Xin Xu, Xiang-Zhi Kong, Zeng-Guang Ren, Zhang-Yong Xia, Huai-Qian Qu, Le-Xin Wang.   

Abstract

OBJECTIVE: This study was designed to investigate the relation between plasma von Willebrand factor (VWF) or endothelin-1 (ET-1) and post-carotid artery stenting (CAS) restenosis.
MATERIALS AND METHODS: Plasma levels of VWF and ET-1 were measured in 61 patients (36 males, mean age 64.4 ± 6.8 years) before and after CAS. The mean follow-up time was 13.8 ± 1.7 months (range, 6-63). In-stent restenosis was defined as a >10% narrowing of the vascular lumen with or without ischemic symptoms following CAS.
RESULTS: In-stent restenosis was identified in 14 (23%) patients, including 3 with >50% restenosis. In the restenosis group, mean VWF and ET-1 levels at 2 weeks, 1 and 6 months after CAS were higher than the baseline levels (p < 0.05 or p < 0.01). Mean levels of VWF and ET-1 in the restenosis group were higher than in the non-restenosis group within 6 months after CAS (p < 0.05 or p < 0.01).
CONCLUSION: Persistent elevation in plasma VWF and ET-1 within the first 6 months of CAS was found in patients with in-stent restenosis.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22571957     DOI: 10.1159/000337940

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  3 in total

Review 1.  High-density lipoprotein: a novel target for antirestenosis therapy.

Authors:  Kai Yin; Devendra K Agrawal
Journal:  Clin Transl Sci       Date:  2014-07-15       Impact factor: 4.689

Review 2.  Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence.

Authors:  Nina Buchtele; Michael Schwameis; James C Gilbert; Christian Schörgenhofer; Bernd Jilma
Journal:  Thromb Haemost       Date:  2018-05-30       Impact factor: 5.249

3.  Acute myocardial infarction caused by tumor-associated thrombotic thrombocytopenic purpura: case report.

Authors:  Jun Wang; Xiaomin Cai; Xunmin Cheng; Ping Song; Shisen Jiang; Jianbin Gong
Journal:  Med Princ Pract       Date:  2013-08-21       Impact factor: 1.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.